Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Alzheimer's Disease Neuroimaging Initiative 4
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233
Banner Alzheimer's Institute, Phoenix, Arizona, United States, 85006
Barrow Neurological Institute, Phoenix, Arizona, United States, 85013
Banner Sun Health Research Institute, Sun City, Arizona, United States, 85351
University of California, Irvine, Irvine, California, United States, 92697
University of California, San Diego, La Jolla, California, United States, 92037
University of California, Los Angeles, Los Angeles, California, United States, 90024
University of Southern California, Los Angeles, California, United States, 90033
Stanford University, Palo Alto, California, United States, 94304
University of California, San Francisco, San Francisco, California, United States, 94158
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
55 Years to 90 Years
ALL
Yes
University of Southern California,
Michael Weiner, MD, STUDY_DIRECTOR, University of California, San Francisco
Paul Aisen, MD, PRINCIPAL_INVESTIGATOR, USC Alzheimer's Therapeutic Research Institute (ATRI)
Ronald Petersen, MD, PHD, PRINCIPAL_INVESTIGATOR, Mayo Clinic
2027-07-31